DUBLIN – (BUSINESS WIRE) – January 7, 2022–
the “China Insulin Glargine Market Investigation Report 2021-2025” the report was added to ResearchAndMarkets.comoffer.
According to the market research, the sales value of Insulin Glargine showed an upward trend from 2016 to 2020 in China, reaching CNY 960.49 million in 2020. Sales growth in 2020 has slowed compared to previous years.
The main reason is that the COVID-19 outbreak has impacted the hospital’s overall diagnostic and treatment activity. Insulin Glargine sales value CAGR in the Chinese market is 5.45% from 2016 to 2020.
Insulin Glargine is a long-acting human insulin analogue that can control a patient’s blood sugar more efficiently and stably. It is often used to treat type 1 and type 2 diabetes. Its original research manufacturer is Sanofi and its trade name is Lantus, which entered the Chinese market in 2004. In 2020, in addition to the company original research, other Chinese market manufacturers of Glargine insulin are Gan & Lee Pharmaceuticals Co., Ltd. and Zhuhai United Laboratories Co., Ltd.
The analyst predicts that from 2021 to 2025, Insulin Glargine sales in China will experience recovery growth with the improvement of the epidemic and normal functioning of the hospital’s overall diagnostic and treatment business. In addition, its sales will also increase due to the expansion of the market.
The number of diabetic patients in China is the largest in the world, and there is a great demand for medicines for the treatment of diabetes. Glargine insulin belongs to the third generation of insulin. Compared with other types of insulin, third generation insulin has greater advantages in terms of onset of action, peak performance and duration of action, indicating that the insulin glargine market has room for growth in China.
Additionally, the key Insulin Glargine patent expired in 2015, and more generic drugs will appear on the Insulin Glargine market in the future. Therefore, the price of Glargine insulin is expected to continue to fall, leading to increased sales volume.
- The impact of COVID-19 on the Chinese insulin glargine market
- China Insulin Glargine Sales Value 2016-2020
- Competitive Landscape of the Chinese Insulin Glargine Market
- Glargine insulin price in China
- China Glargine Insulin Price by Regions and Manufacturers
- Analysis of factors affecting the development of the Chinese insulin glargine market
- China Insulin Glargine Market Outlook 2021-2025
Main topics covered:
1 Relevant concepts of insulin Glargine
1.1 Indications for insulin glargine
1.2 Development of insulin Glargine in China
1.3 Government approval of Glargine insulin in China
1.4 The impact of COVID-19 on Glargine insulin sales in China
2 China Insulin Glargine Sales, 2016-2020
2.1 Sales value of insulin Glargine
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Insulin Glargine Sales Volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 China Insulin Glargine Sales by Dosage Form, 2016-2020
2.3.2 Analysis of other dosage forms
3 China Insulin Glargine Major Manufacturers Analysis, 2016-2020
3.1 Major Manufacturers Insulin Glargine Market Share Analysis
3.1.1 Market Share by Sales Value Survey
3.1.2 Market Share by Sales Volume Survey
3.2 Sanofi-Aventis Deutschland GmbH Germany
3.2.1 Company profile
3.2.2 Sales of LANTUS & TOUJEO (Sanofi-Aventis Deutschland GmbH Germany’s Insulin Glargine) in China
3.3 Gan & Lee Pharmaceuticals Co., Ltd.
3.3.1 Company profile
3.3.2 Sales of BASALIN (Insulin Glargine by Gan & Lee Pharmaceuticals Co., Ltd.) in China
3.4 Zhuhai United Laboratories Co., Ltd.
3.4.1 Company profile
3.4.2 USLEN (Zhuhai United Laboratories Co., Ltd.) Insulin Glargine Sales in China
4 Glargine Insulin Price for Different Manufacturers in China, 2020-2021
4.1 Sanofi-Aventis Deutschland GmbH Germany (LANTUS & TOUJEO)
4.2 Gan & Lee Pharmaceuticals Co., Ltd. (BASALIN)
4.3 Zhuhai United Laboratories Co., Ltd. (USLEN)
5 China Insulin Glargine Market Outlook, 2021-2025
5.1 Factors Influencing the Development of Chinese Insulin Glargine Market
5.1.1 The impact of COVID-19 on the Chinese insulin glargine market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
For more information on this report, visit https://www.researchandmarkets.com/r/rgchit
View source version on businesswire.com:https://www.businesswire.com/news/home/20220107005250/en/
Laura Wood, Senior Press Director
For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
KEYWORD: CHINA ASIA PACIFIC
INDUSTRY KEYWORD: HEALTH DIABETES
SOURCE: Research and markets
Copyright Business Wire 2022.
PUB: 07/01/2022 07:14 / DISC: 07/01/2022 07:14